Yu-bo Zhou

发表

Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies

Yongzhou Hu, Tao Wang, Jianwei Yang, 2021, Acta pharmacologica Sinica.

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

Jia Li, Yifan Zhang, An-hui Gao, 2021, Acta pharmacologica Sinica.

LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation

Jun-qing Du, Yu-bo Zhou, Jia Li, 2009, Acta Pharmacologica Sinica.

Discovery and characterization of a novel inhibitor of CDC25B, LGH00045

Yi Zang, Hai-ping Yu, Q. Shen, 2008, Acta Pharmacologica Sinica.

Interfering MSN-NONO complex–activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer

Shenglin Huang, Yuanyuan Qin, Hongqi Li, 2020, Science Advances.

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma

Lei Xu, An-hui Gao, Chunmei Xia, 2020, Acta Pharmacologica Sinica.

Exploring the mechanism of the PTP1B inhibitors by molecular dynamics and experimental study.

Jia Li, Li-xin Gao, Chun Zhang, 2023, Journal of molecular graphics & modelling.

Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.

G. Wei, Bo Feng, Jia Li, 2023, Acta Pharmacologica Sinica.

Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment

Jia Li, Aimin Ren, Chun Zhang, 2023, Molecules.